Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

Kristian Reich, April W. Armstrong, Richard G. Langley et al. · The Lancet · 2019 · 376 citations

Medicine, Dermatology, Immunology +12

Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Richard B. Warren, Catherine Smith, Zenas Z N Yiu et al. · Journal of Investigative Dermatology · 2015 · 369 citations

Medicine, Clinical Sciences, Dermatology +9

Keratinocyte Overexpression of IL-17C Promotes Psoriasiform Skin Inflammation

Andrew Johnston, Yi Fritz, Sean M. Dawes et al. · The Journal of Immunology · 2013 · 304 citations · Full text

Medicine, Dermatology, Immunology +17

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study

Andrew Blauvelt, Kristian Reich, Tsen‐Fang Tsai et al. · Journal of the American Academy of Dermatology · 2016 · 304 citations

Medicine, Dermatology, Immunology +14

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

Kristian Reich, Kim Papp, Andrew Blauvelt et al. · The Lancet · 2021 · 297 citations

Medicine, Dermatology, Pharmacology +9